Cited by 2,340Hemoglobinopathies and Related DisordersBlood groups and transfusionHemophilia Treatment and Research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Open access

Charache, Samuel, Terrin, Michael L., Moore, Richard D., Dover, George J., Barton, Franca B., Eckert, Susan V., McMahon, Robert P., Bonds, Duane R.·1995·New England Journal of Medicine

DOI 10.1056/nejm199505183322001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. METHODS: In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. RESULTS: Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. CONCLUSIONS: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199505183322001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An introduction to probability theory and its applications
(1958) · Journal of the Franklin Institute · doi:10.1016/0016-0032(58)90688-4 · Cited by 29,621
Applied Regression Analysis
Draper, N. R., & Smith, H. (2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,993
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,869
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Self-citation
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., Eckert, S. V., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Self-citation
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication
Lori, F., Malykh, A., Cara, A., Sun, D. K., Weinstein, J. N., Lisziewicz, J., & Gallo, R. C. (1994) · Science · doi:10.1126/science.7973634 · Cited by 317
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2555.bloodjournal79102555 · Cited by 301
Self-citation
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
Dover, G. J., Brusilow, S. W., & Charache, S. (1994) · Blood · doi:10.1182/blood.v84.1.339.bloodjournal841339 · Cited by 229
Self-citation

Show all 26 references

Research works printed but not linked: 10

Dover GJ, 1994, Blood, 84, 339, 10.1182/blood.V84.1.339.339 · DOI
1994, Blood, 84, 404a
Kalbfleisch JD, Prentice RL. The stastistical analysis of failure time data. New York: John Wiley, 1980:1-20, 70-142.
Ferm VH, 1966, Arch Pathol, 81, 174
Weichselbaum RR, Hallahan DE, Chen GTY. Biological and physical basis to radiation oncology. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:539-66.
Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:698-814.
Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
Fruchtman SM, 1994, Blood, 84, 518a
Boivin P, 1993, Nouv Rev Fr Hematol, 35, 491
Triadou P, 1994, Nouv Rev Fr Hematol, 36, 367

Sorted by citations

Items 701–800 of 1,004

Pathophysiology and recent therapeutic insights of sickle cell disease
Shah, F., & Dwivedi, M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03977-9 · Cited by 36
Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea
Singh, S. A., Koumbourlis, A. C., & Aygün, B. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21480 · Cited by 39
The Role of the Inherited Disorders of Hemoglobin, the First “Molecular Diseases,” in the Future of Human Genetics
Weatherall, D. J. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153500 · Cited by 39
“The widespread use of hydroxyurea has been shown to improve the course of sickle cell anemia in both children and adults (19).”
Background
Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells
Joiner, C. H., Jiang, M., Claussen, W. J., Roszell, N. J., Yasin, Z., & Franco, R. S. (2001) · Blood · doi:10.1182/blood.v97.12.3976 · Cited by 39
Involvement of Germ Cell Apoptosis in the Induction of Testicular Toxicity Following Hydroxyurea Treatment
Shin, J., Mori, C., & Shiota, K. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8593 · Cited by 39
Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study
Sommet, J., Alberti, C., Couque, N., Verlhac, S., Haouari, Z., Mohamed, D., François, M., Missud, F., Holvoet, L., Elmaleh, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13916 · Cited by 38
“The two other factors identified, reticulocyte count and HbF levels, could be indirectly modified by hydroxycarbamide (Charache et al, 1995; Wang et al, 2011).”
Background
Mortal quintet of sickle cell diseases.
Helvacı, M. R., Gökçe, C., Davran, R., Akküçük, S., Uğur, M., & Oruç, C. (2015) · PubMed Central · Cited by 38
Pathophysiology and principles of management of the many faces of the acute vaso‐occlusive crisis in patients with sickle cell disease
Ballas, S. K. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12460 · Cited by 39
Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea
Nottage, K. A., Ware, R. E., Winter, B., Smeltzer, M. P., Wang, W. C., Hankins, J. S., Dertinger, S. D., Shulkin, B. L., & Aygün, B. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12361 · Cited by 38
The influence of hydroxyurea on oxidative stress in sickle cell anemia
Torres, L. S., da Silva, D. G. H., Belini-Junior, E., de Almeida, E. A., Lobo, C. L. D. C., Cançado, R. D., Ruiz, M. A., & Bonini-Domingos, C. R. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120106 · Cited by 39
Complications of sickle cell anaemia in children in Northwestern Tanzania
Saidi, H., Smart, L. R., Kamugisha, E., Ambrose, E. E., Soka, D., Peck, R. N., & Makani, J. (2016) · Hematology · doi:10.1080/10245332.2015.1101976 · Cited by 38
Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era
Hankins, J. S., Penkert, R. R., Lavoie, P. T., Tang, L., Sun, Y., & Hurwitz, J. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216636723 · Cited by 38
Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 39
Sickle Hepatopathy
Praharaj, D. L., & Anand, A. C. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.08.003 · Cited by 39
“Hydroxyurea has been shown to reduce the annual frequency and rate of hospitalization due to painful crisis.(77) However, its benefit in preventing hepatic sequestration and intrahepatic cholestasis is controversial.”
Background
Perinatal Outcome in Sickle Cell Anemia: A Prospective Study from India
Daigavane, M. M., Jena, R. K., & Kar, T. (2013) · Hemoglobin · doi:10.3109/03630269.2013.828301 · Cited by 38
The Xmn1 polymorphic site 5′ to the Gγ gene and its correlation to the Gγ:Aγ ratio, age at first blood transfusion and clinical features in β-Thalassemia patients from Western Iran
Nemati, H., Rahimi, Z., & Bahrami, G. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9566-7 · Cited by 38
High expression of the cGMP‐specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils
Almeida, C. B., Traina, F., Lanaro, C., Canalli, A. A., Saad, S. T. O., Costa, F. F., & Conran, N. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07264.x · Cited by 39
Low adjusted‐dose acenocoumarol therapy in sickle cell disease: A pilot study
Schnog, J. B., Kater, A. P., Gillavry, M. R. M., Duits, A. J., Lard, L. R., van der Dijs, F. P. L., Brandjes, D. P. M., Cate, H. T., van Eps, L. W. S., & Rojer, R. A. (2001) · American Journal of Hematology · doi:10.1002/ajh.1175 · Cited by 38
Induction of Fetal Hemoglobin Synthesis in Children With Sickle Cell Anemia on Low-Dose Oral Sodium Phenylbutyrate Therapy
Resar, L. M. S., Segal, J. B., Fitzpatric, L. K., Friedmann, A. M., Brusilow, S. W., & Dover, G. J. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200212000-00011 · Cited by 38
Self-citation
MANAGEMENT OF SICKLE CELL DISEASE: RECENT ADVANCES AND CONTROVERSIES
Castro, O. L. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01565.x · Cited by 38
Stroke in Saudi Children
Al-Sulaiman, A. A., Bademosi, O., Ismail, H. M., & Magbool, G. M. (1999) · Journal of Child Neurology · doi:10.1177/088307389901400505 · Cited by 38
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Horan, J., & Lerner, N. B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422114 · Cited by 38
Vascular complications of sickle cell disease
Usmani, A., & Machado, R. F. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189008 · Cited by 38
Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease
Newman, T. V., Yang, J., Suh, K., Jonassaint, C. R., Kane‐Gill, S. L., & Novelli, E. M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.44546 · Cited by 37
The effect of hydroxyurea on compound heterozygotes for sickle cell‐hemoglobin D‐Punjab—A single centre experience in eastern India
Patel, S., Purohit, P., Mashon, R. S., Dehury, S., Meher, S., Sahoo, S., Dash, S. S., Das, K., Das, P., & Patel, D. K. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25004 · Cited by 37
“VOC was defined as an acute painful event that required oral/injectable analgesics and that lasted for at least 4 hours when no other cause could explain the symptom [18,19].”
Background
Drugs for preventing red blood cell dehydration in people with sickle cell disease
Nagalla, S., & Ballas, S. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003426.pub5 · Cited by 37
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub‐Saharan Africa
McGann, P. T., Williams, T. N., Olupot‐Olupot, P., TOMLINSON, G. A., Lane, A., da Fonseca, J. L. R., Kitenge, R., Mochamah, G., Wabwire, H., Stuber, S. E., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25034 · Cited by 37
Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost‐effective and reduces iron overload
Dedeken, L., Lê, P.-Q., Rozen, L., Kenz, H. E., Huybrechts, S., Devalck, C., Diallo, S., Heijmans, C., & Ferster, A. (2018) · Transfusion · doi:10.1111/trf.14575 · Cited by 37
How I manage red cell transfusions in patients with sickle cell disease
Rees, D. C., Robinson, S. E., & Howard, J. (2018) · British Journal of Haematology · doi:10.1111/bjh.15115 · Cited by 37
Microparticles in sickle cell disease
Romana, M., Connes, P., & Key, N. S. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189014 · Cited by 37
Genetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 39
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers
Shah, N., Bhor, M., Latrémouille-Viau, D., Sharma, V. K., Puckrein, G. A., Gagnon‐Sanschagrin, P., Khare, A., Singh, M. K., Serra, E., Davidson, M., et al. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1813144 · Cited by 37
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 40
Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome
Ogu, U. O., Badamosi, N. U., Camacho, P. E., Freire, A. X., & Adams-Graves, P. E. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s291394 · Cited by 43
Haemoglobin F modulation in childhood sickle cell disease
Trompeter, S., & Roberts, I. A. G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07482.x · Cited by 37
Psychosocial Considerations in Sickle Cell Disease (SCD): The Transition from Adolescence to Young Adulthood
Baskin, M. L., Collins, M. H., Brown, F., Griffith, J. R., Samuels, D., Moody, A. L., Thompson, M. P., Eckman, J. R., & Kaslow, N. J. (1998) · Journal of Clinical Psychology in Medical Settings · doi:10.1023/a:1026206204009 · Cited by 37
Deferiprone as an oral iron chelator in sickle cell disease
Voskaridou, E., Douskou, M., Terpos, E., Stamoulakatou, A., Meletis, J., Ourailidis, A., Papassotiriou, I., & Loukopoulos, D. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1015-7 · Cited by 37
Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Lapouméroulie, C., Benkerrou, M., Odièvre, M. H., Ducrocq, R., Brun, M., & Élion, J. (2005) · PubMed · Cited by 37
Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferation
Esrick, E. B., McConkey, M. E., Lin, K. I., Frisbee, A. L., & Ebert, B. L. (2015) · American Journal of Hematology · doi:10.1002/ajh.24019 · Cited by 35
The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations
Brandow, A. M., Weisman, S. J., & Panepinto, J. A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22874 · Cited by 36
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
Teng, J., Hejazi, S., Hiddingh, L., de Carvalho, L. A., de Gooijer, M. C., Wakimoto, H., Barazas, M., Tannous, M., Chi, A. S., Noske, D. P., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox198 · Cited by 36
Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events
Brandow, A. M., Hansen, K., Nugent, M., Pan, A. Y., Panepinto, J. A., & Stucky, C. L. (2018) · Pain · doi:10.1097/j.pain.0000000000001407 · Cited by 36
Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients with Sickle Cell Anaemia
Eleutério, R. M. N., Nascimento, F. O., de Araújo, T. G., de Castro, M. F., Filho, T. P. D. A., Filho, P. A. M., Eleutério, J., Elias, D. B. D., & Lemes, R. P. G. (2019) · Advances in Hematology · doi:10.1155/2019/4397150 · Cited by 38
DNA hypo‐methylating agents and sickle cell disease
Saunthararajah, Y., Lavelle, D., & DeSimone, J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05064.x · Cited by 36
Effective control of sickle cell disease with hydroxyurea therapy
Singh, H., Dulhani, N., Kumar, B., Singh, P. K., & Tiwari, P. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.62409 · Cited by 36
Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability
Gutsaeva, D. R., Montero-Huerta, P., Parkerson, J. B., Yerigenahally, S. D., Ikuta, T., & Head, C. A. (2014) · Blood · doi:10.1182/blood-2013-06-510180 · Cited by 36
In vitro antisickling effects of Xylopia aethiopica and Monodora myristica
Uwakwe, A. A., & N, N. R. (2008) · Journal of Medicinal Plants Research · doi:10.5897/jmpr.9000749 · Cited by 36
The Association Between Hydroxyurea Treatment and Pain Intensity, Analgesic Use, and Utilization in Ambulatory Sickle Cell Anemia Patients
Smith, W. R., Ballas, S. K., McCarthy, W. F., Bauserman, R. L., Swerdlow, P. S., Steinberg, M. H., & Waclawiw, M. A. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01096.x · Cited by 36
Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient’s compliance
Adewoyin, A. S., Oghuvwu, S. O., & Awodu, O. A. (2017) · African Health Sciences · doi:10.4314/ahs.v17i1.31 · Cited by 36
Hydroxyurea Can Be Used to Increase Mouse c-kit+Thy-1.1loLin−/loSca-1+ Hematopoietic Cell Number and Frequency in Cell Cycle In Vivo
Uchida, N., Friera, A. M., He, D., Reitsma, M. J., Tsukamoto, A. S., & Weissman, I. L. (1997) · Blood · doi:10.1182/blood.v90.11.4354 · Cited by 36
Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy
Iyamu, E. W., Cecil, R., Parkin, L., Woods, G. M., Ohene‐Frempong, K., & Asakura, T. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05772.x · Cited by 36
Umbilical cord blood stem cells: Application for the treatment of patients with hemoglobinopathies
Kelly, P. F., Kurtzberg, J., Vichinsky, E. P., & Lubin, B. H. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)80009-1 · Cited by 36
Sickle Cell Disease: From Genetics to Curative Approaches
Hardouin, G., Magrin, E., Corsia, A., Cavazzana, M., Miccio, A., & Semeraro, M. (2023) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120122-081037 · Cited by 40
Neonatal screening improves sickle cell disease clinical outcome in Belgium
Lê, P.-Q., Ferster, A., Dedeken, L., Vermylen, C., Vanderfaeillie, A., Rozen, L., Heijmans, C., Huybrechts, S., Devalck, C., COTTON, F. J., et al. (2017) · Journal of Medical Screening · doi:10.1177/0969141317701166 · Cited by 35
A dose‐escalation phase IIa study of 2,2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease
Kutlar, A., Reid, M. E., Inati, A. C., Taher, A. T., Abboud, M. R., El-Beshlawy, A. M., Buchanan, G. R., Smith, H. P., Ataga, K. I., Perrine, S. P., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23533 · Cited by 35
“Treatment duration was 26 weeks to assess potential delayed Hb F response as previously reported with hydroxyurea [1].”
Method
Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme
Cançado, R. D., Lobo, C. L. D. C., Ângulo, I. L., de Araújo, P. I. C., & de Jesus, J. A. (2009) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842009005000076 · Cited by 35
Novel insights in the management of sickle cell disease in childhood
Iughetti, L. (2016) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v5.i1.25 · Cited by 35
NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease
Field, J. J., Majerus, E. M., Ataga, K. I., Vichinsky, E. P., Schaub, R. G., Mashal, R. D., & Nathan, D. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171067 · Cited by 35
“Hydroxyurea, a highly efficacious therapy for SCD, reduces VO pain rate by 50%, a reduction in VO which confers a significant mortality benefit [42,43].”
Background
Improving Medication Adherence with Two-way Short Message Service Reminders in Sickle Cell Disease and Asthma
Pernell, B. M., DeBaun, M. R., BECKER, K. L., Rodeghier, M., Bryant, V., & Cronin, R. M. (2017) · Applied Clinical Informatics · doi:10.4338/aci-2016-12-ra-0203 · Cited by 33
National trends in hydroxyurea and opioid prescribing for sickle cell disease by office‐based physicians in the United States, 1997‐2017
Su, Z. T., Segal, J. B., Lanzkron, S., & Ogunsile, F. J. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4860 · Cited by 35
“Conclusions: This study suggests a robust increase in hydroxyurea prescribing for children with SCD.”
BackgroundInfluential
Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia
Chandra, J., Parakh, N., Sidharth, Singh, N., Sharma, S., Goel, M. K., & Pemde, H. K. (2021) · Indian Pediatrics · doi:10.1007/s13312-021-2254-y · Cited by 34
Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
Baldwin, Z. K., Jiao, B., Basu, A., Roth, J. A., Bender, M. A., Elsisi, Z., JOHNSON, K., Cousin, E. M., Ramsey, S. D., & Devine, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00330-w · Cited by 35
“Hydroxyurea is recommended for all patients with the most severe forms and has proven efficacy for the reduction in VOC and hospitalizations, but the drug is underprescribed and often not taken regularly [6, 7].”
Background
Multi‐modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndrome
Reagan, M. M., DeBaun, M. R., & Frei‐Jones, M. J. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22808 · Cited by 35
Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin
Skarpidi, E., Vassilopoulos, G., Li, Q., & Stamatoyannopoulos, G. (2000) · Blood · doi:10.1182/blood.v96.1.321 · Cited by 35
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
Estcourt, L. J., Fortin, P. M., Hopewell, S., Trivella, M., Doree, C. J., & Abboud, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012389.pub2 · Cited by 35
Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells
Bonvicini, F., Bua, G., Conti, I., Manaresi, E., & Gallinella, G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.022 · Cited by 35
Telomere length in myelodysplastic syndromes
Boultwood, J., Fidler, C., Kušec, R., Rack, K. A., Elliott, P., Atoyebi, O. A., Chapman, R., Oscier, D. G., & Wainscoat, J. S. (1997) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199712)56:4 · Cited by 88
Cytokines and Soluble Adhesion Molecules in Sickle Cell Anemia Patients during Hydroxyurea Therapy
Saleh, A. W., Duits, A. J., Gerbers, A., de Vries, C., & Hillen, H. F. P. (1998) · Acta Haematologica · doi:10.1159/000040859 · Cited by 35
Hydroxyurea in Two Pregnant Women with Sickle Cell Anemia
Byrd, D. C., Pitts, S. R., & Alexander, C. K. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.18.1459.30901 · Cited by 35
Psychological therapies for sickle cell disease and pain
Anie, K. A., & Green, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001916.pub2 · Cited by 35
Sickle cell disease in children: an update of the evidence in low- and middle-income settings
Odame, I. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323633 · Cited by 36
“20 Later, an RCT in children and young adults with SCA aged 2–22 years and with severe clinical disease showed reduced number of hospitalisations as well as days of hospital-isation.”
Background
A phase 1/2 trial of HQK‐1001, an oral fetal globin inducer, in sickle cell disease
Kutlar, A., Ataga, K. I., Reid, M. E., Vichinsky, E. P., Neumayr, L., Blair‐Britt, L., Labotka, R., Glass, J., Keefer, J. R., Wargin, W. A., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23306 · Cited by 34
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea
Okam, M. M., Esrick, E. B., Mandell, E., Campigotto, F., Neuberg, D. S., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-635391 · Cited by 34
Predictors of Abnormal Bone Mass Density in Adult Patients with Homozygous Sickle-Cell Disease
Garadah, T. S., Hassan, A. B., Jaradat, A., Diab, D. E., Kalafalla, H. O., Kalifa, A. K., Sequeira, R. P., & Alawadi, A. H. A. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s24501 · Cited by 34
Abdominal Ultrasound With Scintigraphic and Clinical Correlates in Infants With Sickle Cell Anemia: Baseline Data From the BABY HUG Trial
McCarville, M. B., Luo, Z., Huang, X., Rees, R. C., Rogers, Z. R., Miller, S. T., Thompson, B., Kalpatthi, R. V., Wang, W. C., & the BABY HUG Investigators (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.4664 · Cited by 34
Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia
Quinn, C. T., & Miller, S. T. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.07.004 · Cited by 34
Increase in Brain Tumor Permeability in Glioma-Bearing Rats with Nitric Oxide Donors
Yin, D., Wang, X., Konda, B. M., Ong, J. M., Hu, J., Sacapano, M. R., Ko, M. K., Espinoza, A. J., Irvin, D. K., Shu, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1826 · Cited by 34
Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease
Steinberg, M. H., Voskaridou, E., Kutlar, A., Loukopoulos, D., Koshy, M., Ballas, S. K., Castro, O. L., & Barton, F. B. (2003) · American Journal of Hematology · doi:10.1002/ajh.10264 · Cited by 34
Self-citation
The molecular mechanism of fetal hemoglobin reactivation
Lavelle, D. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.08.002 · Cited by 34
The Role of RIB Infarcts in the Acute Chest Syndrome of Sickle Cell Diseases
Rucknagel, D. L. (2001) · Pediatric Pathology & Molecular Medicine · doi:10.1080/15513810109168607 · Cited by 32
Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia
Boueya, I. L., Sandhow, L., Albuquerque, J. R. P., Znaidi, R., & Passaro, D. (2024) · Leukemia · doi:10.1038/s41375-024-02453-x · Cited by 33
Clinical and laboratory profile of patients with sickle cell anemia
Sant’Ana, P. G. D. S., Araujo, A. M., Pimenta, C. T., Bezerra, M. L. P. K., Borges, S. P., Neto, V. M., Dias, J. D. S., Lopes, A. D. F., Rios, D. R. A., & Pinheiro, M. D. B. (2016) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2016.09.007 · Cited by 33
A systematic review of the literature for severity predictors in children with sickle cell anemia
Meier, E. R., Fasano, R. M., & Levett, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.01.014 · Cited by 33
“The remaining three studies utilized the absolute reticulocyte count (ARC) as a marker for SCA severity and found that higher ARC was associated with cerebral vasculopathy (including stroke), early hospitalization for VOE and splenic sequestration, but not ACS, and death [38–40].”
BackgroundInfluential
Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients
Uchida, N., Fujita, A., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.029 · Cited by 33
“Currently, hydroxyurea (HU) is the only Food and Drug Administration (FDA)-approved treatment in the United States and acts principally through the induction of fetal hemoglobin thereby reducing sickling.(1,2) However, responses to HU are variable, with H um an G en e T he ra py C lin ic al D ev el op m en t”
Opioid treatment for acute and chronic pain in patients with sickle cell disease
Carroll, C. P. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134534 · Cited by 33
Fetal hemoglobin induction by histone deacetylase inhibitors involves generation of reactive oxygen species
Hsiao, C.-H., Li, W., Lou, T., Baliga, B. S., & Pace, B. S. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2005.12.009 · Cited by 33
Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome
Brachet, C., Azzi, N., Demulder, A., Devalck, C., Gourdin, A., Gulbis, B., Klein, A., Lê, P.-Q., Loop, M., Sariban, E., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704443 · Cited by 33
Sickle Cell Anemia in the Female Patient
McKenzie, N. D., Gilles, J. M., Jacques, E., & Harrington, T. J. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000216976.15100.29 · Cited by 33
Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium
Haynes, J., Obiako, B. O., Hester, R. B., Baliga, B. S., & Stevens, T. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01068.2007 · Cited by 33
Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
Kamikura, Y., Wada, H., Yamada, A., Shimura, M., Hiyoyama, K., Shiku, H., Tanigawa, M., Nishikawa, H., Yamada, N., Isaka, N., et al. (1997) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199707)55:4 · Cited by 48
Rationale for the Use of Hydroxyurea as an Anti-Human Immunodeficiency Virus Drug
Lori, F., & Lisziewicz, J. (2000) · Clinical Infectious Diseases · doi:10.1086/313851 · Cited by 33
Valproic Acid and Augmentation of Fetal Hemoglobin in Individuals With and Without Sickle Cell Disease
Selby, R., Nisbet‐Brown, E., Basran, R. K., Chang, L., & Olivieri, N. F. (1997) · Blood · doi:10.1182/blood.v90.2.891 · Cited by 33
Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin
Kim‐Shapiro, D. B., King, S., Bonifant, C. L., Kolibash, C. P., & Ballas, S. K. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(97)00132-3 · Cited by 33
Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
Nottage, K. A., Hankins, J. S., Smeltzer, M. P., Mzayek, F., Wang, W. C., Aygün, B., & Gurney, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072077 · Cited by 32
Severity of Brazilian sickle cell disease patients: Severity scores and feasibility of the Bayesian network model use
Belini-Junior, E., da Silva, D. G. H., Torres, L. S., Okumura, J. V., Lobo, C. L. D. C., & Bonini-Domingos, C. R. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.01.011 · Cited by 32
“The molecular basis for HbS formation is known, but only the mutation (HBB, glu6val, rs334) is not sufficient to explain the heterogeneous phenotype found in SCD patients, other factors such as HbF levels [2–7], α-thalassemia co-inheritance [8–13], genetic polymorphisms [14–21], hydroxyurea use [22–26] and environment…”
Background
The trials and hopes for drug development in sickle cell disease
Ataga, K. I., & Stocker, J. W. (2015) · British Journal of Haematology · doi:10.1111/bjh.13548 · Cited by 32
Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
Uchida, N., Hsieh, M. M., Raines, L. N., Haro‐Mora, J. J., Demirci, S., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2019) · Nature Communications · doi:10.1038/s41467-019-12456-3 · Cited by 33
Molecular Medicine: Found in Translation
Orkin, S. H. (2021) · Med · doi:10.1016/j.medj.2020.12.011 · Cited by 36
Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials
Gyamfi, J., Ojo, T., Epou, S., Cohen, A., Dike, L., Adenikinju, D., Enechukwu, S., Vieira, D. L., Nnodu, O. E., Ogedegbe, G. G., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246700 · Cited by 34
Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria
Ofakunrin, A. O. D., Okpe, E. S., Afolaranmi, T., Olaosebikan, R., Kanhu, P. U., Adekola, K., Dami, N., & Sagay, A. S. (2021) · African Health Sciences · doi:10.4314/ahs.v21i2.36 · Cited by 32

Authors: Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R.
Affiliations: Johns Hopkins University (US)
Maryland Medical Research Institute (US)
National Heart, Lung, and Blood Institute (US)
ORCID: Terrin, Michael L.
Moore, Richard D.
Barton, Franca B.
McMahon, Robert P.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-05-18
Volume: 332
Issue: 20
Pages: 1317-1322
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199505183322001
OpenAlex: W2313541759
Semantic Scholar: 2c0939e2f6480b519903bb15870e5b894887e70d
Cited by: 2,340
References: 26
Citations by year: 2026: 67 · 2025: 97 · 2024: 77 · 2023: 88 · 2022: 95 · 2021: 92 · 2020: 80 · 2019: 78 · 2018: 85 · 2017: 104 · 2016: 114 · 2015: 101 · 2014: 82 · 2013: 79 · 2012: 73
FWCI: 34.43
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
National Institutes of Health (5u01hl045696-05)
National Heart, Lung, and Blood Institute (UO1-HL 45696, UO1 HL 45692, U01HL045692)
National Center for Research Resources (RR00046, M01RR000046)
Topics: Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Health Sciences › Medicine › Hematology › Blood groups and transfusion
Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords: hydroxyurea, sickle cell disease, vaso-occlusive crisis, fetal hemoglobin, blood transfusion, myelosuppression, treatment efficacy, adverse effects
MeSH terms: Adult, Anemia, Sickle Cell, Double-Blind Method, Female, Follow-Up Studies, Humans, Hydroxyurea, Male, Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks